Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation

被引:42
|
作者
Lum, Deirdre A. [1 ]
Sokol, Eric R. [1 ]
Berek, Jonathan S. [1 ]
Schulkin, Jay [2 ]
Chen, Ling [3 ]
McElwain, Cora-Ann [2 ]
Wright, Jason D. [3 ]
机构
[1] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA
[2] Amer Coll Obstetricians & Gynecologists, 409 12th St SW, Washington, DC 20024 USA
[3] Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA
关键词
American College of Obstetricians and Gynecologists; American Association of Gynecologic Laparoscopists; Food and Drug Administration warning; Power morcellation; Survey; OBSTETRICIAN-GYNECOLOGISTS; UTERINE; LEIOMYOSARCOMA; HYSTERECTOMY; LEIOMYOMA; WOMEN;
D O I
10.1016/j.jmig.2016.01.019
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Study Objective: To determine whether members of the AAGL Advancing Minimally Invasive Gynecologic Surgery Worldwide (AAGL) and members of the American College of Obstetricians and Gynecologists Collaborative Ambulatory Research Network (ACOG CARN) have changed their clinical practice based on the 2014 Food and Drug Administration (FDA) warnings against power morcellation. Design: A survey study. Setting: Participants were invited to complete this online survey (Canadian Task Force classification II-2). Patients: AAGL and ACOG CARN members. Interventions: An online anonymous survey with 24 questions regarding demographics and changes to clinical practice during minimally invasive myomectomies and hysterectomies based on the 2014 FDA warnings against power morcellation. Measurements and Main Results: A total of 615 AAGL members and 54 ACOG CARN members responded (response rates of 8.2% and 60%, respectively). Before the FDA warnings, 85.8% and 86.9%, respectively, were using power morcellation during myomectomies and hysterectomies. After the FDA warnings, 71.1% and 75.8% of respondents reported stopping the use of power morcellation during myomectomies and hysterectomies. The most common reasons cited for discontinuing the use of power morcellation or using it less often were hospital mandate (45.6%), the concern for legal consequences (16.1%), and the April 2014 FDA warning (13.9%). Nearly half of the respondents (45.6%) reported an increase in their rate of laparotomy. Most (80.3%) believed that the 2014 FDA warnings have not led to an improvement in patient outcomes and have led to harming patients (55.1%). Conclusion: AAGL and ACOG CARN respondents reported decreased use of power morcellation during minimally invasive gynecologic surgery after the 2014 FDA warnings, the most common reason cited being hospital mandate. Rates of laparotomy have increased. Most members surveyed believe that the FDA warnings have not improved patient outcomes. (C) 2016 AAGL. All rights reserved.
引用
收藏
页码:548 / 556
页数:9
相关论文
共 50 条
  • [1] Reflections about the impact caused by the Food and Drug Administration (FDA) warning against uterine and/or fibroid power morcellation
    Oliveira Brito, Luiz Gustavo
    Rosa e Silva, Julio Cesar
    Nogueira, Antonio Alberto
    [J]. REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2015, 37 (07): : 299 - 301
  • [2] SAFETY WARNINGS ABOUT POWER MORCELLATION IN HYSTERECTOMY: A SIMULATION OF NATIONAL IMPACT
    Xu, X.
    Desai, V. B.
    Schwartz, P. E.
    Gross, C. P.
    Lin, H.
    Wright, J. D.
    [J]. VALUE IN HEALTH, 2021, 24 : S12 - S12
  • [3] Trends in Mode of Hysterectomy After the US Food and Drug Administration Power Morcellation Advisory
    Ottarsdottir, Helga
    Cohen, Sarah L.
    Cox, Mary
    Vitonis, Allison
    Einarsson, Jon I.
    [J]. OBSTETRICS AND GYNECOLOGY, 2017, 129 (06): : 1014 - 1021
  • [4] Outpatient Fluoroquinolone Prescription Fills in the United States, 2014 to 2020: Assessing the Impact of Food and Drug Administration Safety Warnings
    Buehrle, Deanna J.
    Wagener, Marilyn M.
    Clancy, Cornelius J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (07)
  • [5] Changes in Myomectomy Practice After the US Food and Drug Administration Safety Communication on Power Morcellation
    Stentz, Natalie C.
    Cooney, Laura G.
    Sammel, Mary
    Shah, Divya K.
    [J]. OBSTETRICS AND GYNECOLOGY, 2017, 129 (06): : 1007 - 1013
  • [6] Impact of the food and drug administration safety warnings and removal of indications for use of oral quinolones
    Tran, Phuong T.
    Antonelli, Patrick J.
    Hincapie-Castillo, Juan M.
    Winterstein, Almut G.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 151 - 152
  • [7] Google searches and medical publication trends since the 2014 US Food and Drug Administration position on power morcellation: Do these translate into patient awareness?
    Liou, N. S.
    Mallick, R.
    Aref-Adib, M.
    Odejinmi, F.
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2019, 243 : 168 - 172
  • [8] US Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas
    Parker, William H.
    Kaunitz, Andrew M.
    Pritts, Elizabeth A.
    Olive, David L.
    Chalas, Eva
    Clarke-Pearson, Daniel L.
    Berek, Jonathan S.
    [J]. OBSTETRICS AND GYNECOLOGY, 2016, 127 (01): : 18 - 22
  • [9] Impact of Food and Drug Administration (FDA) paediatric antidepressant warnings on stock prices of pharmaceutical manufacturers
    Valluri, Satish
    Lyons, Bridget M.
    Mullins, C. Daniel
    [J]. JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2010, 1 (02) : 61 - 67
  • [10] Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation
    Harris, John A.
    Swenson, Carolyn W.
    Uppal, Shitanshu
    Kamdar, Neil
    Mahnert, Nichole
    As-Sanie, Sawsan
    Morgan, Daniel M.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (01) : 98.e1 - 98.e13